Zuellig Pharma
Concise Prescribing Info
Ranitidine HCl
NSAID-associated duodenal & benign gastric ulcer. Post-op ulcer. Oesophageal reflux. Zollinger-Ellison syndrome. Prophylaxis of stress ulceration in seriously ill patients, recurrent haemorrhage from peptic ulcer & Mendelson's syndrome. Tab/syr H pylori-associated duodenal ulcer. Symptomatic relief in GERD. Chronic episodic dyspepsia. Prevention of NSAID-associated duodenal ulcers especially in patients w/ history of peptic ulcer disease.
Dosage/Direction for Use
Tab/syr Adult ≤12 yr Acute duodenal ulcer & benign gastric ulcer 150 mg bd or 300 mg at night for 4 wk. Duodenal ulcer 300 mg bd for 4 wk. Long-term management of duodenal & benign gastric ulcer 150 mg at night. Acute treatment of NSAID-associated peptic ulcer 150 mg bd or 300 mg at night. Prophylaxis of NSAID-associated duodenal ulcer 150 mg bd. H pylori-associated duodenal ulcer 150 mg bd or 300 mg at night given w/ oral amoxicillin 750 mg tds + metronidazole 500 mg tds for 2 wk. Post-op ulcer 150 mg bd for 4 wk. Acute reflux oesophagitis 150 mg bd or 300 mg at night up to 8 or 12 wk. Moderate to severe oesophagitis 150 mg qds for up to 12 wk. Long-term treatment of reflux oesophagitis 150 mg bd. Symptomatic relief of oesophageal acid reflux 150 mg bd for 2 wk. Zollinger-Ellison syndrome 150 mg tds, may be increased up to 6 g daily. Chronic episodic dyspepsia 150 mg bd for up to 6 wk. Prophylaxis of Mendelson's syndrome 150 mg 2 hr before anaesth & 150 mg on the previous evening. Obstet patient in labour 150 mg every 6 hr. Prophylaxis of haemorrhage from stress ulceration in seriously ill patient or recurrent haemorrhage in patient bleeding from peptic ulceration 150 mg bd. Inj 50 mg slow IV every 6-8 hr; 25 mg/hr intermittent IV infusion for 2 hr, repeated every 6-8 hr interval or 50 mg IM every 6-8 hr. Prophylaxis of Mendelson's syndrome 50 mg IM or slow IV inj 45-60 min before general anaesth induction. Prophylaxis of upper GI haemorrhage from stress ulceration in seriously ill patient 50 mg slow IV as priming dose, followed by 0.125-0.25 mg/kg/hr continuous IV infusion.
May be taken with or without food.
Special Precautions
Exclude gastric malignancy prior to therapy. History of acute porphyria; peptic ulcer; chronic lung disease, diabetes or immunocompromised patients. Pregnancy & lactation. Concomitant use w/ NSAIDs especially in elderly. Syr High-risk patients (eg, alcoholism, liver disease, epilepsy, brain injury or disease). Childn. Inj Patients w/ predisposing factors of cardiac rhythm disturbances. High dose.
Adverse Reactions
Rarely, hypersensitivity reactions eg, urticaria, angioneurotic oedema, fever, bronchospasm, hypotension & chest pain; transient & reversible changes in liver function tests; skin rash.
Drug Interactions
Altered prothrombin time w/ coumarin anticoagulants eg, warfarin. Increased plasma levels of procainamide & N-acetylprocainamide. Increased absorption of triazolam, midazolam, glipizide. Decreased absorption of ketoconazole, atazanavir, delaviridine, gefitnib. Reduced absorption by high-dose sucralfate.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BA02 - ranitidine ; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Zantac inj 50 mg/2 mL
5 × 1's
Zantac syr 150 mg/10 mL
(peppermint flavour) 200 mL x 1's
Zantac tab 150 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in